....and yet another stem cell partnership (from an investment house). Its as if the investment community (outside of Australia) actually have a clue of the potential of regenrative medicine's effects on the landscape of medical treatments:
https://www.fiercebiotech.com/cro/ncardia-inks-60m-funding-deal-to-expand-discovery-and-commercial-production-services-for-stem
Roche "At Roche we are utilizing the enormous potential of human stem cells to test potential new drugs in vitro"
Bristol-Myers Squibb "cell-based therapies that use a person’s own cells are unlocking new potential in the fight against some of the most difficult-to-treat cancers...autologous chimeric antigen receptor (CAR) T cell therapy"
Pfizer "for more than a decade, Pfizer has been using animal or adult stem cells in its laboratories to help screen new compounds and identify safer and more effective medicines"
Eli Lilly - stem cells in diabetes; Astra Zenica - oncology etc, etc, etc
Partnerhsip between:
Biogen/Sangamo
J&J (Janssen)/Fate
Novartis/Sangamo
Bayer/Atara
Sanofi/Aventis
Novartis/Mesoblast (maybe!)
Fujifilm/Cynata
Sanofi/Kadmon
etc, etc.
The use of stem-cells, be they tissue specific, emryonic, and autologous, induced pluripotent or otherwise are taking off in development.
Johnson and Johnson's vaccine received a bit of furore over using fetal (retinal) embryonic cells in the research that led to its vaccines. Ironically the media overlooked Pfizer/Moderna's use of the fetal cell line HEK-293 in the confirmation phase to ensure the vaccines work.
Emryonic and other stem-cells are, quietly, increasingly being used in the labs of big Pharma in much of their research. There is little chance J&J leaves this very morally acceptable treatment of using a patients own stem-cells in a safe and very convenient way to address degenerative tendons. Its such an easy, uncontentioius and quick commercial possibility compared to most stem-cell treatments.
- Forums
- ASX - By Stock
- OCC
- J&J Partnership
J&J Partnership, page-354
-
- There are more pages in this discussion • 49 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OCC (ASX) to my watchlist
(20min delay)
|
|||||
Last
41.5¢ |
Change
-0.010(2.35%) |
Mkt cap ! $88.02M |
Open | High | Low | Value | Volume |
42.0¢ | 42.5¢ | 41.5¢ | $36.29K | 86.40K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
3 | 11096 | 41.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
42.0¢ | 26292 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 18091 | 0.415 |
6 | 27374 | 0.410 |
2 | 26293 | 0.405 |
7 | 82300 | 0.400 |
2 | 3291 | 0.395 |
Price($) | Vol. | No. |
---|---|---|
0.420 | 26292 | 2 |
0.430 | 26556 | 3 |
0.435 | 65000 | 2 |
0.440 | 36400 | 2 |
0.445 | 99431 | 2 |
Last trade - 15.55pm 01/10/2024 (20 minute delay) ? |
Featured News
OCC (ASX) Chart |
The Watchlist
BM8
BATTERY AGE MINERALS LTD
Nigel Broomham, CEO
Nigel Broomham
CEO
Previous Video
Next Video
SPONSORED BY The Market Online